CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.28B, above the global median of $1.15B
- PositionCurrent ratio is 0.67×, lower than 95% of its Biotechnology peers (median 5.5×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.60BCNY1.28B · vs all stocks (USD)
Revenue (TTM)
980.25MCNY145.77M · vs all stocks (USD)
Profit Margin
-39.83%vs Biotechnology peers
Beta
0.3720xvs all stocks
52-Week Change
-37.13%vs all stocks
Market Capitalization
8.60BCNY1.28B · vs all stocks (USD)
Enterprise Value
9.12BCNY1.36B · vs all stocks (USD)
Forward P/E
-30.25xvs Biotechnology peers
Price to Sales (TTM)
8.69xvs Biotechnology peers
Price to Book (MRQ)
38.02xvs Biotechnology peers
Enterprise to Revenue
9.30xvs Biotechnology peers
Enterprise to EBITDA
-25.47xvs Biotechnology peers
Gross Margin
81.34%vs Biotechnology peers
Profit Margin
-39.83%vs Biotechnology peers
Operating Margin
-57.97%vs Biotechnology peers
Return on Assets (TTM)
-12.29%vs Biotechnology peers
Return on Equity (TTM)
-93.09%vs Biotechnology peers
Revenue (TTM)
980.25MCNY145.77M · vs all stocks (USD)
Revenue per Share (TTM)
2.36CNYUpdated Aug 21, 2026Quarterly Revenue Growth
21.80%vs Biotechnology peers
Gross Profit (TTM)
783.42MCNY116.50M · vs all stocks (USD)
EBITDA (TTM)
-358.15MCNY-53.26M · vs all stocks (USD)
Net Income (TTM)
-390.44MCNY-58.06M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
55.56%vs Biotechnology peers
Operating Cash Flow (TTM)
-115.94MCNY-17.24M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-429.02MCNY-63.80M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
935.22MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
197.22MCNYFY2025 · Dec 31, 2025Gross Profit
738.00MCNYFY2025 · Dec 31, 2025Operating Income
-346.27MCNY-51.49M · vs all stocks (USD)
Pre-tax Income
-331.65MCNYFY2025 · Dec 31, 2025Income Tax Expense
292.39KCNYFY2025 · Dec 31, 2025Net Income
-331.94MCNYFY2025 · Dec 31, 2025EBIT
-311.58MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-205.98MCNYFY2025 · Dec 31, 2025Research & Development
800.15MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
273.32MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.25MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.85MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
20.07MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.8000CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.8000CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
414.93MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
414.93MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-331.94MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-536.13MCNYFY2025 · Dec 31, 2025Free Cash Flow
-657.69MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
218.61MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-331.94MCNYFY2025 · Dec 31, 2025Other Non-cash Items
21.26MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-166.03MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-59.42MCNYFY2025 · Dec 31, 2025Capital Expenditures
-121.56MCNYFY2025 · Dec 31, 2025Purchase of Investments
-880.00MCNYFY2025 · Dec 31, 2025Sale of Investments
971.75MCNYFY2025 · Dec 31, 2025Other Investing Activity
21.11MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-8.69MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
360.27MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-298.53MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-20.39MCNYFY2025 · Dec 31, 2025Other Financing Charges
-58.00KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
41.29MCNYFY2025 · Dec 31, 2025Shares Outstanding
414.08MSharesUpdated Aug 21, 2026Float Shares
107.34MSharesUpdated Aug 21, 2026% Held by Insiders
68.86%vs all stocks
% Held by Institutions
6.68%vs all stocks
Total Cash (MRQ)
247.80MCNY36.85M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5980CNYUpdated Aug 21, 2026Total Debt (MRQ)
781.37MCNY116.20M · vs all stocks (USD)
Total Debt to Equity (MRQ)
3.49xvs Biotechnology peers
Current Ratio (MRQ)
0.6670xvs Biotechnology peers
Book Value per Share (MRQ)
0.5410CNYUpdated Aug 21, 2026Total Assets
2.29BCNY340.15M · vs all stocks (USD)
Total Current Assets
958.56MCNYFY2025 · Dec 31, 2025Total Liabilities
1.91BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.33BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
543.94MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.37BCNYFY2025 · Dec 31, 2025Cash
218.61MCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
218.61MCNYFY2025 · Dec 31, 2025Accounts Receivable
164.70MCNYFY2025 · Dec 31, 2025Inventory
312.42MCNYFY2025 · Dec 31, 2025Accounts Payable
198.69MCNYFY2025 · Dec 31, 2025Short-term Debt
311.83MCNYFY2025 · Dec 31, 2025Other Current Liabilities
703.48KCNYFY2025 · Dec 31, 2025Long-term Debt
374.21MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
144.81MCNYFY2025 · Dec 31, 2025Common Stock (Book)
414.08MCNYFY2025 · Dec 31, 2025Retained Earnings
-3.09BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
376.03MCNY55.92M · vs all stocks (USD)
52-Week Low
15.57CNYUpdated Aug 21, 202652-Week High
35.34CNYUpdated Aug 21, 202652-Week Change
-37.13%vs all stocks
Beta
0.3720xvs all stocks
50-Day MA
17.93CNYUpdated Aug 21, 2026200-Day MA
21.61CNYUpdated Aug 21, 2026Avg 10-Day Volume
6.33MSharesUpdated Aug 21, 2026Avg 30-Day Volume
4.41MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.9400CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.67×, lower than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 0.67Industry median: 5.50Industry P5: 0.97Peers compared: 197
Debt-to-equity is 3.49×, higher than 95% of its Biotechnology peers (median 0.1×)Significant
Debt-to-equity: 3.49Industry median: 0.10Industry P95: 2.96Peers compared: 197
Price-to-book is 38.02×, higher than 95% of its Biotechnology peers (median 5.36×)Significant
Price-to-book: 38.02Industry median: 5.36Industry P95: 37.43Peers compared: 197
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.81Profit Margin: -0.40
Financial Health
Altman Z-Score 0.55: distress zoneCritical
Altman Z-Score: 0.55
Low earnings qualitySignificant
Earnings Quality Score: -0.64
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.28B, above the global median of $1.15BNotable
Market cap (USD): 1,278,355,891.968Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ardelyx Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Ringpu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jade Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Celltrion Pharm, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xencor Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk